Loading company…
Tessera Therapeutics develops genome engineering technologies to address genetic diseases.
Tessera Therapeutics is developing Gene Writing™ technology to make genomic modifications, including programs targeting genetic disorders such as sickle cell disease. Founded in 2018 and based in Cambridge, US, it raised USD 400.00 mn in a Series C round on 18 December 2024, with investors including ARTIS Ventures and the Bill & Melinda Gates Foundation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in